28 November 2024 · 1 min read
The AI-driven techbio revolution is heating up:
Cradle, a Netherlands-based generative AI biotech startup, just raised a $73M Series B — a round that's truly big by EU standards and signals the explosive growth of AI-driven drug discovery. I see real parallels to the rise of Veeva, and the coming years promise to be game-changing.
Filed under Tech Bio
The AI-driven techbio revolution is heating up:
Cradle, a Netherlands-based generative AI biotech startup, has just raised an impressive $73M Series B led by Silicon Valley VC giant IVP, alongside Index Ventures and Kindred Capital VC. This comes only a year after their $23M Series A - highlighting the explosive growth and appetite for AI solutions in drug discovery and development.
This round is truly big by EU standards. It's encouraging to see Europe holding its ground and competing fiercely with the US and Israel in this space.
The SaaS-driven transformation of drug discovery and development is a market to watch, with parallels to the rise of players like Veeva in the commercial and marketing arena (and increasingly betting on the R&D space as well). The coming years promise to be game-changing.
Related insights
16 Dec 2025
OpenAI is among the backers of a biotech founded in 2024 that is already valued at $1.3B.
22 Sept 2025
From AI to superintelligence: Lila just raised $235M to turbocharge its 'AI Science Factories
12 May 2026
Isomorphic about to raise $2bn - and why I'm not sure that's a good thing
14 Apr 2026
Hyperscalers in AI drug discovery: why Anthropic and AWS are moving into techbio